High Efficiency Cell Engineering With The MaxCyte Electroporation Platform

When it comes to advancing cell engineering, a key challenge is the ability to maintain high cell viability and recovery, particularly with sensitive cell types like primary cells and stem cells. Overcoming these hurdles is essential for a wide range of applications, including CRISPR, cell-based assays, and the production of proteins and viruses.

In this seminar, Dr. Hyatt Balke-Want of Stanford University details how non-viral gene-editing platforms can be used to efficiently manufacture CAR-T cells, with the goal of increasing accessibility to these therapies for patients. The seminar also highlights several case studies that showcase how academic and industry labs alike are utilizing cutting-edge technology to achieve high-efficiency engineering of these challenging cell types.

To learn more, access the full seminar below.